Among these, biosimilars have drawn significant investor attention. Manchanda highlighted Biocon as an early mover in the space, stating, “Biocon has been there for a long time, and the next two years are expected to be very strong for it.” He also identified Dr Reddy’s and Lupin as strong contenders, adding that “these companies have a solid pipeline, and over a four- to five-year horizon, they could build a biosimilars business of USD 0.5 billion to USD 1 billion.”
